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ABSTRACT 
Little is known about the etiologic profile of triple-negative breast cancer (TNBC; ER-/PR-
/HER2-), a breast cancer subtype associated with high mortality and inadequate therapeutic options. We 
undertook the study to assess the risk of TNBC among women 45 years of age and younger in relation to 
demographic/lifestyle factors, reproductive history, and oral contraceptive (OC) use. Study participants 
were ascertained in two prior population-based, case-control studies. Eligible cases included all primary 
invasive breast cancers among women ages 20-45 in the Seattle-Puget Sound area, diagnosed between 
January 1983 and December 1992 for whom complete data was obtained for ER, PR and HER2 status 
(n=897; including n=187 TNBC cases). Controls were age matched and ascertained via random digit 
dialing. OC use ≥1 year was associated with a 2.5-fold increased risk of TNBC (95% CI 1.4-4.3) and no 
significantly increased risk of non-TNBC (P heterogeneity .008). Further, the risk among OC users conferred 
by longer OC duration and by more recent use was significantly greater for TNBC than non-TNBC (P 
heterogeneity .02 and .01, respectively). Among women ≤40 years, the relative risk of TNBC associated with 
OC use ≥1 year was 4.2 (95% CI 1.9-9.3), whereas there was no significantly increased risk with OC use 
for non-TNBC among women ≤40 years, nor for TNBC or non-TNBC among women 41-45 years of age. 
In conclusion, significant heterogeneity exists for the association of OC use and breast cancer risk 
between TNBC and non-TNBC among young women, lending support to a distinct etiology. 
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INTRODUCTION 
Breast cancer is a strikingly heterogeneous disease with variable clinical, pathologic, and 
molecular features. Microarray expression patterns and immunohistochemical signatures can distinguish 
breast cancer subtypes and likely reflect important differences in pathogenesis and etiology (1-4). Current 
breast cancer treatment strategies rely on the characterization of estrogen and progesterone hormone 
receptor (ER/PR) protein expression status and more recently, on human epidermal growth factor (HER2) 
protein expression or gene amplification. Breast tumors that fail to express ER/PR and HER2 (triple-
negative breast cancer, or TNBC) account for 10-17% of all breast cancers (5-12).  
Recently, five distinct gene expression profile-based ‘intrinsic’ subtypes were identified by 
cDNA microarray analysis, two derived from ER-positive subtypes (luminal A and B) and three from ER-
negative subtypes (HER2-positive, basal-like and normal-like) (1, 2, 13). Over 90% of TNBC tumors fall 
within the basal-like subgroup, so called for its gene expression profile that mimics basal epithelial cells 
in other parts of the body (usually identified by immunohistochemical staining for the expression of 
cytokeratin 5/6, reduced ER/PR and HER2 expression), and a characteristic morphology that includes 
high proliferative rate, central necrosis, and a pushing border (14, 15). Basal-like breast cancer is 
associated with aggressive histology, unresponsiveness to typical endocrine therapies, poor prognosis, 
and BRCA1-related breast cancer (1-3, 16). 
TNBC constitutes a clinically challenging type of breast cancer that occurs more frequently in 
younger women (<50 years) (6, 7, 9, 10) and African American women (10-12), and is associated with 
significant aggressiveness as compared to other subtypes (5-7, 9-11). Although TNBC is of growing 
interest in the clinical and research community, its etiology remains understudied. We undertook this 
study to evaluate the contribution of known and suspected breast cancer risk factors to TNBC in a large 
population-based study. 
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METHODS 
The cases included in this study were originally ascertained for two prior studies through the 
population-based Seattle-Puget Sound Surveillance, Epidemiology, and End Results (SEER) cancer 
registry. Eligible cases from the first study population included all primary, invasive breast cancers within 
the three county Seattle metropolitan area, diagnosed between January 1, 1983 and April 30, 1990, ages 
21-45. The methods for this study have been described elsewhere (17, 18). The study was confined to 
Caucasians because of the small representation of minorities in the region. Of 898 eligible invasive cases, 
744 (83%) were interviewed. Nine hundred and sixty-one controls were interviewed, representing a 76% 
overall response rate (97% of dialed known residential households successfully screened; 78% 
interviewed). For both studies, controls were identified by random digit dialing (RDD) and frequency 
matched to cases by 5-year age groups. 
 The second population included the Seattle site participants of the multicenter Women’s 
Interview Study of Health (WISH), the methods for which have been described (19). Eligible cases 
included women in the Seattle area diagnosed with invasive breast cancer between May 1, 1990 and 
December 31, 1992, ages 20-44 years. In-person interviews were completed on 542 women (86% of 
eligible Seattle cases with invasive disease). Six hundred and eight Seattle controls were interviewed, 
representing a 71% overall response rate (90% of dialed known residential households successfully 
screened; 78% interviewed). Reference dates were assigned to all participants: age at diagnosis for cases 
and an assigned age for each control to result in an approximately similar age distribution for cases and 
controls. Because the present study focuses on invasive TNBC, in situ cases were excluded. The 
appropriate institutional review boards approved all protocols.  
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In-person interviews of comparable format, covering a broad range of risk factors that included 
lifestyle/demographic factors, reproductive history, and oral contraceptive (OCs) use, were administered 
to participants in both studies. Tumor specimens were obtained for 1019 of the 1286 cases with invasive 
breast cancer who were accrued in the two previous studies. Tissue collection, pathology review, and 
testing for prognostic markers have been discussed previously (20). Briefly, tumor tissue was sufficient 
for immunoperoxidase (IHC) assay on 907 (89.0%) of the tumors. Antibody staining for ER, PR, and 
HER2 was assessed as negative, 1+ (low positive), 2+ (intermediate positive) or 3+ (high positive). 
Scores above negative were considered positive for ER and PR. A distinct membranous staining pattern 
above 1+ (low-positive) was considered positive for HER2. The current study is restricted to cases for 
whom complete ER, PR, and HER2 results were obtained (n=897). 
Breast cancer risk factors were evaluated according to ER, PR and HER2 status. Classification by 
these three markers results in eight different subtype combinations, however, our analyses focus primarily 
on comparisons between TNBC (n=187 [20.8%]) and non-TNBC tumors, due in part to the small number 
of observations with dissimilar ER/PR status in our study population (e.g. ER+/PR-/HER2-, n=57 [6.4%]; 
ER-/PR+/HER2-, n=65 [7.2%]; ER+/PR-/HER2+, n=23 [2.6%]; ER-/PR+/HER2+, n=26 [2.9%]).  
Secondary analyses focus on OC variables and breast cancer defined separately and jointly by ER 
and HER2 status (collapsed across PR status; ER/PR correlation coefficient r=.60), and also stratifed by 
age (≤40 and 41-44), allowing us to determine whether one or two marker classification methods 
produced associations similar to that of TNBC, and compare results with previous ER and HER2 
findings. Further, analyses were repeated stratified by source study and also restricted to participants with 
reference dates after 1985 (the latter due to an ascertainment delay for women with a reference date prior 
to the study’s start in 1986). 
Unordered polytomous logistic regression (STATA mlogit; StataCorp. 2005. Stata Statistical 
Software: Release 9. College Station, TX) was used to determine odds ratios (OR; as an approximation of 
the relative risk) and 95 percent confidence intervals (CI) for the risk of TNBC and non-TNBC, as well as 
for ER and HER2 defined breast cancer. The following known and suspected breast cancer risk factors 
  
6
were examined separately as potential confounders for the main effects of all other risk factors, in age-
adjusted models: age (at reference), race, education, annual income, family history of breast cancer, body 
mass index (BMI; kg/m2) one year prior to reference, smoking history, alcohol consumption, age at 
menarche, number of live births, age at first birth (still or live), lactation history (among parous women), 
abortion history (among gravid women), and OC use (never/<1 year versus ≥1 year, OC duration, age at 
first use, years since first use, and years since last use). Those variables that produced a 10% or greater 
change in the OR for any TNBC risk factor were considered as adjustment factors in the final model. All 
final risk estimates are adjusted for age, family history, lactation history, and OC duration (i.e. 
multivariate-adjusted). Trend tests for ordered categorical exposure variables were performed by 
including a single grouped linear variable in the polytomous logistic regression model. We excluded 
nulliparous women from the trend test for age at first birth to evaluate whether an association with breast 
cancer risk existed beyond the effect of parity alone. To explore whether characteristics of OC use were 
associated with breast cancer risk beyond any effect of never/<1 year versus ≥1 year use, we tested the 
trend of OC duration, age at first use, years since first use, and years since last use among the OC users 
(≥1year) only.  
Odds ratio heterogeneity between tumor subtypes was evaluated by logistic regression restricted 
to cases. For ordered categorical exposure variables, the Pheterogeneity value was based on the significance of 
a linear trend variable; for age at first birth and the characteristics of OC use, Pheterogeneity was limited to 
parous women and OC users ≥1 year, respectively. For dichotomous and nominal exposure variables, 
Pheterogeneity was derived from the significance of removing the variable from models based on log-
likelihood ratio tests. 
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RESULTS 
 In analyses of all 897 breast cancer cases (subtypes combined), the multivariate-adjusted odds 
ratios for examined risk factors were consistent with the effects observed in prior studies of younger 
women (Table 1). Specifically, older age, family history of breast cancer, earlier menarche age, induced 
abortion, and OC use were associated with an increased risk of breast cancer. Risk was decreased in 
relation to greater number of births and younger age at first birth. OC use ≥1 year was associated with a 
modest increased risk of breast cancer, and among OC users only, earlier age at first use further elevated 
the risk. 
Upon examination of the same risk factors in cases with (n=187) and without (n=710) TNBC 
(Table 1), we found that OC use ≥1 year (Pheterogeneity .008), OC duration (Pheterogeneity .02), and years since 
last OC use (Pheterogeneity .01) conferred significantly different risk estimates by case group, and BMI ≥30 
k/m2 was associated with a borderline significant increased risk of TNBC (OR 1.3, 95% CI 0.8-2.2) and a 
non-significant decreased risk of non-TNBC (OR 0.8, 95% CI 0.6-1.2) in women of all ages. Upon 
restriction to women ages 41-45, the risk of TNBC in relation to BMI ≥30 k/m2 was further elevated (OR 
2.2, 95% CI .9-5.24) while that of non-TNBC did not change substantively (OR 0.9, 95% CI 0.5-1.6; 
results not presented). OC use ≥1 year was associated with a 2.5-fold increased risk of TNBC (95% CI 
1.4-4.3) and no significantly increased risk of non-TNBC. Among OC users, risk of TNBC increased with 
longer duration of OC use (Ptrend .05) and fewer years since last OC use (Ptrend .04), relationships that were 
absent for non-TNBC. We attempted to disentangle the effect of OC duration versus recency via stratified 
and adjusted polytomous logistic regression analyses, and found that neither risk factor was a more 
important determinant of risk. 
We also examined the effect of OC variables across HER2 and ER defined breast cancer risk to 
evaluate the influence of each marker separately (Table 2). We found a 2-fold increased risk of ER-
negative breast cancer conferred by OC use ≥1 year (OR 2.0, 95% CI 1.3-2.9), which differed 
significantly from the absence of an association with ER-positive breast cancer (OR 1.1, 95% CI 0.8-1.4; 
Pheterogeneity .005), as did the risk conferred by OC duration (Pheterogeneity .004) and years since last use 
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(Pheterogeneity <.001). The risk of ER-negative breast cancer increased substantially with longer OC 
duration (Ptrend .05) and recency of use (Ptrend .02). For all aspects of OC use, risk estimates were far 
greater for ER- breast cancer than for HER2- breast cancer.  
Ever use of OCs was associated with a modest increased risk of HER2-negative disease (OR 1.4, 
95% CI 1.1-1.9) and a lower non-statistically significant risk of HER2-positive disease (OR 1.2, 95% CI 
0.8-1.7). No significant trends across OC use features were observed in relation to the risk of HER2-
negative breast cancer, but risk of HER2-positive disease did appear to increase with younger age at first 
use (Ptrend .05). Heterogeneity between HER2 subtypes was not statistically significant for any OC use 
variable. 
 Upon further cross-classification by both ER and HER2 (Table 3), we observed significantly 
elevated risk of breast cancer across all OC variables consistently and almost exclusively in the ER-
/HER2- subset; ORs were comparable, only slightly less than those seen in relation to the risk of TNBC. 
The risk of ER-/HER2- breast cancer increased with longer OC duration (Ptrend .03) and fewer years since 
last OC use (Ptrend .04). We observed a large degree of heterogeneity between HER2-negative ER 
subtypes according to OC use ≥ 1 year (Pheterogeneity .01), as well as OC duration (Pheterogeneity <.001) and 
years since last use (Pheterogeneity <.001). 
Finally, we examined the effect of OC use according to TNBC status stratified by age at breast 
cancer diagnosis ≤40 and 41-45 years (Table 4). Among women 41 to 45 years of age, there was no 
significantly increased risk of breast cancer for any aspect of OC use, overall and within TNBC-defined 
subgroups, however we did find significant heterogeneity between the risk of TNBC and non-TNBC 
according to years since last use (Pheterogeneity .01). Among TNBC cases ≤40 years of age, all risk estimates 
for OC use variables were approximately two times greater than those in the combined TNBC age group 
estimates. In women ≤40 years of age, OC use ≥1 year was associated with an over 4-fold increased risk 
of TNBC (OR 4.2, 95% CI 1.9-9.3) and no increased risk of non-TNBC (OR 1.2, 95% CI 0.9-1.7; 
Pheterogeneity <.001). Also among women ≤40 years of age, we found that the risk of breast cancer overall 
and of non-TNBC increased with younger age at first use (Ptrend .02 and .04 respectively).  
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Results did not vary substantively when examined separately by original study source or in 
those with a reference year after 1985. Characteristics of the women from whom we were able to obtain 
sufficient tissue for tumor marker assays differed on a number of factors from those of women for whom 
we were unable to obtain tissue (data not presented). The women whose tumors were not tested were 
younger, more likely to be white, and more likely to have a low annual income. AJCC stage and tumor 
grade did not differ significantly between the tumors available for assay and those unavailable.
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DISCUSSION 
 In this population-based study of breast cancer in women under 45 years of age, the risk 
conferred by OC use varied significantly between TNBC and non-TNBC. OC use ≥1 year was associated 
with a 2.7-fold increased risk of TNBC. The risk of TNBC was further heightened in relation to longer 
OC duration and fewer years since last use. Among women ≤40 years the strength of the OC use 
association with TNBC was further magnified. Similar relationships were not observed in relation to non-
TNBC, providing support for an etiologic distinction. 
 The relationship between OC use and breast cancer risk has been the subject of extensive research 
(17, 19, 21-23). Unlike well-established risk factors such as family history, early menarche, nulliparity, 
and lack of breastfeeding (24-27), the relationship between OC use and breast cancer risk has remained 
less clear. A large pooled analysis (28) and recent meta-analysis (29) have both reported an increased risk 
of breast cancer (approximately 20-30%) in relation to OC use among premenopausal women. Previous 
studies have also shown risk in relation to OC use to be concentrated among younger premenopausal 
women (30, 31). These findings are compatible with the present study and consistent with our prior 
reports on OC use effects in the two study populations from which our study population was drawn (17, 
19). 
 The mechanism through which OC use impacts breast cancer risk in young women is unknown. 
Studies of estrogen’s role in promoting the growth and vascularization of cancer cells have focused 
largely on the transcriptional effects of estrogen binding to its receptor in ER-positive mammary and 
ovarian cancer cells. However, a recent publication has proposed a second mechanism whereby estrogen 
promotes the growth of ER-negative and ER-positive cancer by systematically enhancing angiogenesis 
and stromal cell recruitment (32). 
Interest in the clinical and pathologic characterization of TNBC has grown tremendously in 
recent years, related in part to its poor prognosis and higher frequency in younger and African-American 
women. Although basal-like/TNBC tends to have a poor prognosis compared to other subtypes, it is 
unclear whether this is due to inherent aggressiveness or resistance to systemic therapy. Trastuzumab 
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(Herceptin) and tamoxifen effectively target HER2+ (33, 34) and ER+ (35) breast cancer, respectively, 
but targeted therapies for basal-like/TNBC patients are lacking. Carey et al. reported that TNBC (and less 
common HER2+/ER-) patients had worse survival than luminal subtypes (5), despite higher 
chemosensitivity to conventional anthracycline-based therapy. 
 Few studies to date have focused on etiologic risk factors for basal-like/TNBC, and none have 
focused on young women. Millikan et al. (36) examined common breast cancer risk factors across 
‘intrinsic’ breast cancer subtypes in the population-based Carolina Breast Cancer Study of women ages 
20-74. Among women of all ages, they observed an increased risk of basal-like breast cancer in relation to 
increasing number of live births and younger age at first full-term pregnancy. In a case-only comparison 
of basal-like versus luminal A breast cancer subtypes among women of all ages in relation to OC use, no 
differences were observed. Yang et al. (37) evaluated established breast cancer etiologic factors by 
subtype within the Polish Breast Cancer Study. Among premenopausal women, increasing BMI (per 5 
units) was associated with a borderline-significant increased risk of basal-like breast cancer (OR 1.2, 95% 
CI 0.9-1.6) and a reduced risk of luminal A breast cancer (OR .7, 95% CI 0.6-0.9; Pheterogeneity .003). OC 
use was rare in this population (>60% of participants were postmenopausal) and not significantly 
associated with breast cancer risk overall or within subtypes.  
 Hormone receptor and HER2 defined breast cancers have been the subject of a more extensive 
literature. ER-negative breast cancer is known to be more frequent among young women (38), African 
American women (39), and BRCA1 carriers (40). ER-positive breast cancer is associated with improved 
response to hormonal therapy, longer disease-free intervals, and improved survival (41). Previous studies 
of etiologic heterogeneity among hormone receptor defined breast cancer have reported risk factor 
differences with mixed results. In a systematic literature review, Althuis et al. (42) reported that delayed 
childbearing, nulliparity, and early menarche were commonly associated with an increased risk among 
ER-positive breast cancer only. Several studies that have examined elevated BMI in premenopausal 
women by hormone receptor status have discerned an increased risk of ER-/PR- breast cancer but not 
ER+/PR+ breast cancer (43, 44), while others have not (38, 45, 46). The relationship between OC use and 
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risk of ER-defined breast cancer is somewhat ambiguous. Several studies have reported an increased 
risk of ER-negative breast cancer in young women associated with ever using OCs (38, 47), and long 
duration of use (43, 44), but with varying levels of magnitude and statistical significance.  
 Evidence that breast cancer risk factors operate through HER2 is inconsistent. Within the 
Carolina Breast Cancer Study, Huang et al. (48) found that most recognized breast cancer risk factors did 
not vary by HER2 status; neither high BMI nor OC use were associated with a significantly increased risk 
of HER+ or HER2- breast cancer in premenopausal women. In contrast, Sherman et al. (49) found that 
high BMI was associated with low HER2 levels in premenopausal women (Ptrend .01) within the Polish 
Breast Cancer Study. Some studies of premenopausal women have found an increased risk of HER2-
positive breast cancer in relation to early OC use (50, 51), while others have found no association 
between OC use and either HER2 subtype (48, 52).  
The results of this study should be considered in light of several limitations. Our study population 
contained few non-Caucasians, and given that TNBC is more than twice as common among African 
Americans, similar research is needed in a racially heterogeneous population to evaluate the 
generalizability of our results. Our ability to evaluate age-specific effects was constrained by the small 
number of TNBC cases ages 41-45. It is worth noting that the diagnosis years in this study pre-date the 
incorporation of HER2 and routine ER/PR clinical testing, thus requiring direct testing of samples, which 
was limited by the availability of tumor specimens. We obtained specimens for 1019 of the 1286 women 
in our study (79.2%). To the extent that the availability of tumor specimens was related to features that 
are also related to TNBC, our results may be biased. As with all studies of TNBC, there is also potential 
for misclassification of TNBC due to false negative or false positive IHC results. In particular, our study 
used IHC to assess HER2 expression levels, the accepted standard for HER2 assessment at the time 
assays were completed. Since then, fluorescence in situ hybridization (FISH) has become the standard for 
discrimination of HER2 intermediate IHC scores. Because a portion of the 2+ (intermediate positive) 
tumors would not show amplification by FISH analysis, we may have misclassified some true HER2-
negative cases as HER2 positive. In addition a small number of tumors that exhibit only 1+ (low positive) 
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immunostaining could be falsely low by IHC. For the analyses presented in this study we used the 
standard clinical definition of HER2-negative, which included negative and low positive staining. We 
also repeated all analyses with a purer HER2-negative definition by excluding low positives from the 
TNBC group; results were of similar magnitude, but with wider confidence intervals (data not shown). 
Our study has the strength of being population-based and is the largest of its kind to evaluate 
breast cancer subtypes and etiologic differences in young women. In contrast to the few other studies that 
have examined risk factors by tumor subtype, OC use was common in our study population and extensive 
detail on OC usage patterns was collected, allowing us to assess OC use associations in a thorough 
manner. By excluding non-OC users from trend tests, we were able to discern differences in OC use 
above and beyond ever use, thereby providing additional support for dose-response relationships (53). 
The centralized, blinded nature of tumor specimen testing removed the potential for inter-reviewer bias.  
The strong association between OC use and the risk of TNBC observed in this study and the 
relative scarcity of such studies to date, emphasize the need for future research. Given that we have yet to 
understand whether the poor prognosis associated with TNBC is a reflection of fewer treatment options, 
or is intrinsic to the biology of the disease, the results of etiologic studies such as the present one may 
ultimately play an important role in elucidating the etiologic pathways of TNBC, and in facilitating the 
development of strategies for prevention, treatment, and management of TNBC. 
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Table 1. Multivariate adjusted* case-control odds ratios and 95% confidence intervals for all breast cancer cases, triple-negative and non triple-negative 
cases in relation to known and suspected risk factors among women 45 years of age and younger, 1983-1992. 
 
 
 Triple–negative (ER-/PR-/HER2-) status 
 
 
 
Controls 
(N=1,569) 
 
 
All breast cancer (N=897) 
 
 
Triple-negative (N=187) 
 
Non triple-negative 
(N=710) 
 
 
 n (%) n (%) OR (95% CI) n (%) OR (95% CI) n (%) OR (95% CI) P Value** 
Demographic/Lifestyle factors 
           
  
Age (yrs)             
 <30 155 (  9.9) 35 (  3.9) 1.0 Reference 9 (  4.8) 1.0 Reference 26 (  3.7) 1.0 Reference   
 30-34 297 (18.9) 140 (15.6) 2.1 (1.1-3.9) 38 (20.3) 2.6 (0.8-9.1) 102 (14.4) 2.0 (1.0-3.9)   
 35-39 573 (36.5) 335 (37.3) 2.4 (1.3-4.3) 79 (42.2) 2.9 (0.9-9.8) 256 (36.1) 2.2 (1.2-4.2)   
 40-45 544 (34.7) 387 (43.1) 2.6 (1.4-4.6) 61 (32.6) 2.2 (0.7-7.4) 326 (45.9) 2.7 (1.4-5.1)   
 P for trend     .006   .81   .002   .13 
Race§§             
 White 1482 (94.6) 836 (93.7) 1.0 Reference 178 (95.7) 1.0 Reference 658 (93.2) 1.0 Reference   
 Black 27 (  1.7) 20 (  2.2) 0.9 (0.4-2.5) 3 (  1.6) 0.0 N/A 17 (  2.4) 1.2 (0.5-3.2)   
 Other 58 (  3.7) 36 (  4.0) 0.9 (0.5-1.7) 5 (  2.7) 0.9 (0.3-3.1) 31 (  4.4) 0.9 (0.4-1.8)  .05 
Education             
 <College graduate 1035 (66.0) 572 (63.8) 1.0 Reference 119 (63.6) 1.0 Reference 453 (63.8) 1.0 Reference   
 College graduate 533 (34.0) 325 (36.2) 1.2 (1.0-1.6) 68 (36.4) 1.3 (0.9-2.0) 257 (36.2) 1.2 (1.0-1.6)  .61 
Annual income‡‡             
 <15,000 184 (11.9) 81 (  9.1) 1.0 Reference 14 (  7.5) 1.0 Reference 67 (  9.5) 1.0 Reference   
 15-45/50,000 863 (55.9) 471 (52.9) 1.3 (0.8-1.9) 99 (52.9) 1.2 (0.6-2.6) 372 (52.9) 1.3 (0.8-1.9)   
 45/50,000+ 496 (32.1) 338 (38.0) 1.3 (0.8-1.9) 74 (39.6) 1.5 (0.7-3.2) 264 (37.6) 1.2 (0.8-1.9)   
 P for trend     .39   .24   .64   .55 
Family history of breast cancer             
 None 807 (67.8) 363 (50.3) 1.0 Reference 78 (47.6) 1.0 Reference 285 (51.1) 1.0 Reference   
 1st degree 95 (  8.0) 150 (20.8) 3.0 (2.1-4.1) 37 (22.6) 3.5 (2.1-5.9) 113 (20.3) 2.8 (2.0-4.0)   
 2nd degree only 289 (24.3) 209 (28.9) 1.7 (1.3-2.2) 49 (29.9) 1.8 (1.2-2.8) 160 (28.7) 1.7 (1.3-2.2)  .70 
Body mass index (k/m2)†             
 <18.5  87 (  5.6) 35 (  4.0) 0.7 (0.4-1.2) 6 (  3.2) 0.5 (0.2-1.7) 29 (  4.2) 0.8 (0.4-1.4)   
 18.5 – 24.9 977 (63.4) 578 (65.6) 1.0 Reference 121 (65.1) 1.0 Reference 457 (65.8) 1.0 Reference   
 25.0-29.9  269 (17.4) 151 (17.1) 1.0 (0.7-1.3) 33 (17.7) 1.1 (0.6-1.8) 118 (17.0) 0.9 (0.7-1.3)   
 30+ 209 (13.6) 117 (13.3) 0.9 (0.7-1.3) 26 (14.0) 1.3 (0.8-2.2) 91 (13.1) 0.8 (0.6-1.2)   
 P for trend     .99   .18   .54   .12 
Smoking             
 Never 801 (51.4) 464 (52.2) 1.0 Reference 100 (54.6) 1.0 Reference 364 (51.6) 1.0 Reference   
 Former 332 (21.3) 189 (21.3) 0.9 (0.7-1.2) 34 (18.6) 0.8 (0.5-1.3) 155 (22.0) 0.9 (0.7-1.3)   
 Current 424 (27.2) 236 (26.5) 0.9 (0.7-1.2) 49 (26.8) 1.0 (0.6-1.6) 187 (26.5) 0.9 (0.7-1.2)  .29 
Alcohol use (drinks/wk)             
 None/<1 771 (49.2) 442 (49.3) 1.0 Reference 88 (47.1) 1.0 Reference 354 (49.9) 1.0 Reference   
 1-3 288 (18.4) 152 (17.0) 1.0 (0.7-1.3) 29 (15.5) 0.8 (0.5-1.4) 123 (17.3) 1.0 (0.7-1.4)   
 3+ 507 (32.4) 302 (33.7) 1.1 (0.9-1.4) 70 (37.4) 1.1 (0.7-1.6) 232 (32.7) 1.1 (0.8-1.4)   
 P for trend     .54   .84   .54   .49 
Reproductive factors 
          
  
Age at menarche             
 8-12 737 (47.1) 471 (52.5) 1.0 Reference 98 (52.4) 1.0 Reference 373 (52.5) 1.0 Reference   
 13-14 690 (44.1) 351 (39.1) 0.8 (0.6-1.0) 77 (41.2) 0.8 (0.6-1.2) 274 (38.6) 0.7 (0.6-1.0)   
 15+ 139 (  8.9) 75 (  8.4) 0.8 (0.5-1.2) 12 (  6.4) 0.4 (0.2-1.0) 63 (  8.9) 0.9 (0.6-1.4)   
 P for trend     .03   .05   .11   .33 
Number of live births             
 None 396 (25.2) 232 (25.9) 1.0 Reference 53 (28.3) 1.0 Reference 179 (25.2) 1.0 Reference   
 1-3 1057 (67.4) 621 (69.2) 0.8 (0.5-1.3) 127 (67.9) 0.9 (0.4-1.9) 494 (69.6) 0.8 (0.5-1.3)   
 4+ 116 (  7.4) 44 (  4.9) 0.5 (0.3-1.0) 7 (  3.7) 0.6 (0.2-1.9) 37 (  5.2) 0.5 (0.3-1.0)   
 P for trend     .04   .38   .04   .83 
Age at first birth (yrs)‡             
 None 390 (24.9) 230 (25.7) 1.0 Reference 53 (28.3) 1.0 Reference 177 (25.0) 1.0 Reference   
 <20 264 (16.8) 116 (12.9) 0.6 (0.3-1.0) 19 (10.2) 0.6 (0.2-1.4) 97 (13.7) 0.6 (0.3-1.0)   
 20-29 745 (47.5) 419 (46.8) 0.8 (0.5-1.3) 86 (46.0) 0.9 (0.4-2.0) 333 (47.0) 0.8 (0.5-1.3)   
 30+ 170 (10.8) 131 (14.6) 1.0 (0.6-1.8) 29 (15.5) 1.2 (0.5-3.0) 102 (14.4) 1.0 (0.6-1.8)   
 P for trend§     .002   .03   .009   .49 
Lactation||             
 Never 313 (26.9) 189 (28.5) 1.0 Reference 33 (24.6) 1.0 Reference 156 (29.4) 1.0 Reference   
 <12 494 (42.5) 279 (42.0) 1.1 (0.8-1.4) 63 (47.0) 1.1 (0.7-1.8) 216 (40.8) 1.1 (0.8-1.5)   
 12+ 356 (30.6) 196 (29.5) 1.0 (0.7-1.4) 38 (28.4) 1.0 (0.6-1.7) 158 (29.8) 1.0 (0.7-1.4)   
 P for trend     .97   .99   .98   .78 
Abortion¶             
 Never 950 (72.9) 510 (67.3) 1.0 Reference 98 (64.5) 1.0 Reference 412 (68.0) 1.0 Reference   
 Ever 354 (27.1) 248 (32.7) 1.4 (1.1-1.8) 54 (35.5) 1.4 (0.9-2.2) 194 (32.0) 1.4 (1.1-1.8)  .82 
* Risk factors adjusted for age, family history of breast cancer, breastfeeding history and OC duration  
† 1 yr prior to reference date  
‡ Still and live births 
§ P for trend among parous women only 
|| Among parous women 
¶ Among gravid women 
** Pheterogeneity (association of risk factor with triple-negative vs. non triple-negative breast cancer) 
†† Ptrend and Pheterogeneity among OC users >1 year only 
‡‡ Income categories reflect the fact that the two studies combined for the present study used different cut-offs 
§§ Due to missing data, race was adjusted for age, breastfeeding history and OC duration, but not family history of breast cancer 
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Table 1 continued. Multivariate adjusted* case-control odds ratios and 95% confidence intervals for all breast cancer cases, triple-negative and non 
triple-negative cases in relation to known and suspected risk factors among women 45 years of age and younger, 1983-1992. 
 
 
 Triple –negative (ER-/PR-/HER2-) status 
 
 
 
Controls 
(N=1,569) 
 
 
All breast cancer (N=897) 
 
 
Triple-negative (N=187) 
 
 
Non triple-negative (N=710) 
 
 
 n (%) n (%) OR (95% CI) n (%) OR (95% CI) n (%) OR (95% CI) P Value**
Oral contraceptive use 
        
  
OC use (yrs)             
 Never/<1 407 (25.9) 197 (22.0) 1.0 Reference 22 (11.8) 1.0 Reference 175 (24.7) 1.0 Reference   
 1+ 1162 (74.1) 699 (78.0) 1.3 (1.0-1.7) 165 (88.2) 2.5 (1.4-4.3) 534 (75.3) 1.2 (0.9-1.5)  .008 
OC duration (yrs)††             
 1-<3 327 (20.8) 184 (20.5) 1.3 (0.9-1.7) 35 (18.7) 1.6 (0.9-3.3) 149 (21.0) 1.2 (0.9-1.7)   
 3-<6 357 (22.8) 220 (24.6) 1.4 (1.0-2.0) 51 (27.3) 2.8 (1.5-5.3) 169 (23.8) 1.2 (0.9-1.7)   
 6+ 478 (30.5) 295 (32.9) 1.3 (1.0-1.8) 79 (42.2) 2.9 (1.6-5.3) 216 (30.5) 1.1 (0.8-1.5)   
 P for trend     .85   .05   .45   .02 
Age at first use (yrs)††             
 22+ 260 (16.6) 159 (17.7) 1.2 (0.9-1.7) 31 (16.6) 2.0 (1.0-4.1) 128 (18.1) 1.1 (0.8-1.6)   
 18-<22 674 (43.0) 390 (43.5) 1.2 (0.9-1.6) 92 (49.2) 2.3 (1.3-4.1) 298 (42.0) 1.1 (0.8-1.4)   
 <18 228 (14.5) 150 (16.7) 1.9 (1.3-2.7) 42 (22.5) 3.7 (1.9-7.2) 108 (15.2) 1.6 (1.1-2.3)   
 P for trend     .05   .13   .10   .84 
Years since first use††             
 1-<15 313 (19.9) 132 (14.7) 1.3 (0.8-1.9) 36 (19.3) 2.4 (1.1-5.1) 96 (13.5) 1.1 (0.7-1.6)   
 15-<20 462 (29.4) 277 (30.9) 1.3 (1.0-1.8) 78 (41.7) 3.0 (1.6-5.4) 199 (28.1) 1.1 (0.8-1.5)   
 20+ 387 (24.7) 290 (32.4) 1.4 (1.0-1.9) 51 (27.3) 2.0 (1.1-4.0) 239 (33.7) 1.3 (0.9-1.8)   
 P for trend     .27   .74   .25   .74 
Years since last use††             
 Current 120 (  7.6) 43 (  4.8) 1.0 (0.6-1.8) 16 (  8.6) 3.1 (1.2-7.6) 27 (  3.8) 0.7 (0.4-1.4)   
 1-<5 190 (12.1) 116 (12.9) 1.9 (1.3-2.9) 31 (16.6) 4.2 (2.0-8.6) 85 (12.0) 1.6 (1.1-2.5)   
 5-<10 255 (16.3) 136 (15.2) 1.2 (0.8-1.7) 41 (21.9) 3.0 (1.6-5.9) 95 (13.4) 0.9 (0.6-1.3)   
 10-<15 339 (21.6) 213 (23.8) 1.3 (1.0-1.8) 55 (29.4) 2.6 (1.4-4.8) 158 (22.3) 1.2 (0.8-1.6)   
 15+ 258 (16.4) 191 (21.3) 1.3 (0.9-1.8) 22 (11.8) 1.2 (0.6-2.6) 169 (23.8) 1.3 (0.9-1.8)   
 P for trend     .86   .04   .39   .01 
* Risk factors adjusted for age, family history of breast cancer, breastfeeding history and OC duration  
† 1 yr prior to reference date  
‡ Still and live births 
§ P for trend among parous women only  
|| Among parous women 
¶ Among gravid women 
** Pheterogeneity (association of risk factor with triple-negative vs. non triple-negative breast cancer) 
†† Ptrend and Pheterogeneity among OC users >1 year only  
‡‡ Income categories reflect the fact that the two studies combined for the present study used different cut-offs 
§§ Due to missing data, race was adjusted for age, breastfeeding history and OC duration, but not family history of breast cancer 
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Table 2. Multivariate adjusted* case-control odds ratios and 95% confidence intervals for all breast cancer cases defined by HER2 and ER status in relation to OC use among women 45 years 
of age and younger, 1983-1992. 
Controls 
ER status 
  
HER2 status 
 
(N=1,569) 
 
ER-negative (N=364) 
 
ER-positive (N=533) 
 
  HER2-negative (N=608) 
 
HER2-positve (N=289) 
 
 
 n (%) n (%) OR (95% CI) n (%) OR (95% CI) P Value† n (%) OR (95% CI) n (%) OR (95% CI) P Value§
Oral contraceptive use 
 
    
 
OC use (yrs)               
 Never/<1 407 (25.9) 59 (16.2) 1.0 Reference 138 (25.9) 1.0 Reference  124 (20.4) 1.0 Reference 73 (25.3) 1.0 Reference  
 1+ 1162 (74.1) 305 (83.8) 2.0 (1.3-2.9) 394 (74.1) 1.1 (0.8-1.4) .005 483 (79.6) 1.4 (1.1-1.9) 216 (74.7) 1.2 (0.8-1.7) .27 
OC duration (yrs)‡                
 1-<3 327 (20.8) 66 (18.1) 1.5 (0.9-2.4) 118 (22.2) 1.2 (0.8-1.7)  126 (20.8) 1.4 (0.9-2.0) 58 (20.1) 1.1 (0.7-1.8)  
 3-<6 357 (22.8) 98 (26.9) 2.2 (1.4-3.4) 122 (22.9) 1.1 (0.8-1.6)  159 (26.2) 1.6 (1.1-2.3) 61 (21.1) 1.2 (0.7-1.9)  
 6+ 478 (30.5) 141 (38.7) 2.2 (1.4-3.4) 154 (28.9) 0.9 (0.6-1.3)  198 (32.6) 1.4 (1.0-2.0) 97 (33.6) 1.2 (0.8-1.8)  
 P for trend     .05   .15  .004  .94    .79  .89 
Age at first use (yrs)‡                
 22+ 260 (16.6) 64 (17.6) 1.7 (1.1-2.9) 95 (17.9) 1.0 (0.7-1.5)  112 (18.5) 1.4 (0.9-2.0) 47 (16.3) 1.0 (0.6-1.6)  
 18-<22 674 (43.0) 170 (46.7) 1.8 (1.2-2.8) 220 (41.4) 1.0 (0.7-1.3)  270 (44.5) 1.3 (1.0-1.8) 120 (41.5) 1.1 (0.7-1.6)  
 <18 228 (14.5) 71 (19.5) 2.8 (1.7-4.6) 79 (14.8) 1.4 (0.9-2.2)  101 (16.6) 1.9 (1.3-2.9) 49 (17.0) 1.8 (1.1-2.9)  
 P for trend     .10   .14  .96  .18    .05  .40 
Years since first use‡                
 1-<15 313 (19.9) 70 (19.2) 1.8 (1.1-3.2) 62 (11.7) 1.0 (0.6-1.6)  89 (14.7) 1.4 (0.9-2.2) 43 (14.9) 1.0 (0.6-1.8)  
 15-<20 462 (29.4) 137 (37.6) 2.3 (1.5-3.6) 140 (26.3) 0.9 (0.6-1.3)  200 (32.9) 1.5 (1.1-2.2) 77 (26.6) 1.0 (0.6-1.6)  
 20+ 387 (24.7) 98 (26.9) 1.7 (1.1-2.8) 192 (36.1) 1.2 (0.9-1.7)  194 (32.0) 1.4 (0.9-2.0) 96 (33.2) 1.4 (0.9-2.2)  
 P for trend     .80   .17  .40  .78    .07  .12 
Years since last use‡                
 Current 120 (  7.6) 24 (  6.6) 1.9 (0.9-3.9) 19 (  3.6) 0.6 (0.3-1.4)  27 (  4.4) 0.9 (0.5-1.8) 16 (  5.5) 1.2 (0.5-2.6)  
 1-<5 190 (12.1) 63 (17.3) 3.6 (2.1-6.0) 53 (10.0) 1.3 (0.8-2.0)  76 (12.5) 2.0 (1.3-3.1) 40 (13.8) 1.9 (1.1-3.3)  
 5-<10 255 (16.3) 71 (19.5) 2.2 (1.3-3.6) 65 (12.2) 0.7 (0.5-1.2)  100 (16.5) 1.3 (0.9-2.0) 36 (12.5) 0.9 (0.5-1.5)  
 10-<15 339 (21.6) 91 (25.0) 2.0 (1.3-3.2) 122 (22.9) 1.0 (0.7-1.5)  155 (25.5) 1.6 (1.1-2.2) 58 (20.1) 1.0 (0.6-1.5)  
 15+ 258 (16.4) 56 (15.4) 1.2 (0.7-2.0) 135 (25.4) 1.3 (0.9-1.9)  125 (20.6) 1.3 (0.9-1.9) 66 (22.8) 1.2 (0.8-2.0)  
 P for trend     .02   .07  < .001   .95    .62  .65 
*Risk factors adjusted for age, family history of breast cancer, and breastfeeding history 
† Pheterogeneity (association of risk factor with ER-negative vs. ER-positive breast cancer) 
‡ Ptrend and Pheterogeneity among OC users >1 year only 
§ Pheterogeneity (association of risk factor with HER2-negative vs. HER2-positive breast cancer) 
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Table 3. Multivariate adjusted* case-control odds ratios and 95% confidence intervals for ER-negative and ER-positive 
breast cancer in relation to OC use, stratified by HER2 status among women age 45 years and younger, 1983-1992. 
Controls 
(N=1569) 
 
ER-negative (N=364) 
 
ER-positive (N=533) 
 
 
 n (%) n (%) OR (95% CI) n (%) OR (95% CI) P Value† 
 
  
Among HER2-negative 
  
Oral contraceptive use   n=252 n=356  
OC use (yrs)         
 Never/<1 407 (25.9) 32 (12.7) 1.0 Reference 92 (25.9) 1.0 Reference  
 1+ 1162 (74.1) 220 (87.3) 2.2 (1.4-3.5) 263 (74.1) 1.1 (0.8-1.6) .01 
OC duration (yrs)‡         
 1-<3 327 (20.8) 45 (17.9) 1.4 (0.8-2.6) 81 (22.8) 1.3 (0.9-2.0)  
 3-<6 357 (22.8) 72 (28.6) 2.5 (1.5-4.4) 87 (24.5) 1.2 (0.8-1.8)  
 6+ 478 (30.5) 103 (40.9) 2.5 (1.5-4.2) 95 (26.8) 0.9 (0.6-1.3)  
 P for trend     .03   .05  < .001 
Age at first use‡         
 22+ 260 (16.6) 45 (17.9) 2.0 (1.1-3.6) 67 (18.9) 1.1 (0.7-1.8)  
 18-<22 674 (43.0) 122 (48.4) 2.0 (1.2-3.3) 148 (41.7) 1.0 (0.7-1.5)  
 <18 228 (14.5) 53 (21.0) 3.1 (1.7-5.5) 48 (13.5) 1.3 (0.8-2.2)  
 P for trend     .17   .51  .80 
Years since first use‡         
 1-<15 313 (19.9) 50 (19.8) 2.1 (1.1-4.0) 39 (11.0) 1.0 (0.6-1.9)  
 15-<20 462 (29.4) 104 (41.3) 2.7 (1.6-4.5) 96 (27.0) 1.0 (0.7-1.5)  
 20+ 387 (24.7) 66 (26.2) 1.7 (1.0-3.0) 128 (36.1) 1.2 (0.8-1.8)  
 P for trend     .88   .58  .67 
Years since last use‡         
 Current 120 (  7.6) 19 (  7.5) 2.2 (1.0-5.2) 8 (  2.3) 0.3 (0.1-1.1)  
 1-<5 190 (12.1) 41 (16.3) 3.5 (1.9-6.6) 35 (  9.9) 1.3 (0.7-2.2)  
 5-<10 255 (16.3) 56 (22.2) 2.6 (1.5-4.6) 44 (12.4) 0.8 (0.4-1.3)  
 10-<15 339 (21.6) 72 (28.6) 2.4 (1.4-4.1) 83 (23.4) 1.2 (0.8-1.8)  
 15+ 258 (16.4) 32 (12.7) 1.1 (0.6-2.1) 93 (26.2) 1.3 (0.9-2.1)  
 P for trend     .04   .03  <.001 
 
 Among HER2-positive 
 
 
Oral contraceptive use   n =112 n =177 
 
 
OC use (yrs)          
 Never/<1 407 (25.9) 27 (24.1) 1.0 Reference 46 (26.0) 1.0 Reference   
 1+ 1162 (74.1) 85 (75.9) 1.6 (0.8-3.0) 131 (74.0) 1.0 (0.6-1.5)  .18 
OC duration (yrs)‡          
 1-<3 327 (20.8) 21 (18.8) 1.5 (0.7-3.2) 37 (20.9) 1.0 (0.5-1.7)   
 3-<6 357 (22.8) 26 (23.2) 1.5 (0.7-3.3) 35 (19.8) 1.0 (0.6-1.8)   
 6+ 478 (30.5) 38 (33.9) 1.7 (0.8-3.4) 59 (33.3) 1.0 (0.6-1.7)   
 P for trend     .73   .91   .83 
Age at first use (yrs)‡          
 22+ 260 (16.6) 19 (17.0) 1.4 (0.6-3.2) 28 (15.8) 0.8 (0.4-1.5)   
 18-<22 674 (43.0) 48 (42.9) 1.4 (0.7-2.8) 72 (40.7) 0.9 (0.5-1.4)   
 <18 228 (14.5) 18 (16.1) 2.3 (1.0-5.1) 31 (17.5) 1.5 (0.8-2.8)   
 P for trend     .26   .09   .79 
Years since first use‡          
 1-<15 313 (19.9) 20 (17.9) 1.3 (0.5-3.4) 23 (13.0) 0.9 (0.4-1.8)   
 15-<20 462 (29.4) 33 (29.5) 1.6 (0.8-3.2) 44 (24.9) 0.8 (0.5-1.4)   
 20+ 387 (24.7) 32 (28.6) 1.7 (0.8-3.7) 64 (36.2) 1.3 (0.7-2.2)   
 P for trend     .42   .08   .62 
Years since last use‡          
 Current 120 (  7.6) 5 (  4.5) 1.2 (0.3-4.6) 11 (  6.2) 1.2 (0.5-2.9)   
 1-<5 190 (12.1) 22 (19.6) 3.5 (1.5-8.1) 18 (10.2) 1.2 (0.6-2.6)   
 5-<10 255 (16.3) 15 (13.4) 1.3 (0.6-3.1) 21 (11.9) 0.7 (0.4-1.4)   
 10-<15 339 (21.6) 19 (17.0) 1.3 (0.6-2.8) 39 (22.0) 0.8 (0.5-1.5)   
 15+ 258 (16.4) 24 (21.4) 1.3 (0.6-3.0) 42 (23.7) 1.2 (0.7-2.1)   
 P for trend     .24   .84   .36 
*Risk factors adjusted for age, family history of breast cancer, and breastfeeding history 
† Pheterogeneity (association of risk factor with ER-negative vs. ER-positive breast cancer) 
‡ Ptrend and Pheterogeneity among OC users >1 year only 
 
  
5
 
Table 4. Multivariate adjusted* case-control odds ratios and 95% confidence intervals for all breast cancer cases, triple-negative and non triple-
negative cases in relation to OC risk factors, stratified by age at diagnosis ≤40 and 41-45 years, 1983-1992. 
 
Controls 
 Triple–negative status 
  
 (N=1,569) 
 
All breast cancer (N=897) 
 
Triple-negative (N=187) 
 
Non triple-negative (N=710) 
 
  
 n (%) n (%) OR (95% CI) n (%) OR (95% CI) n (%) OR (95% CI) P Value† 
 
Among women ≤ 40 years of age 
 
Oral contraceptive use n=1156 n=590 n=141 n=449 
 
OC use (yrs)           
 Never/<1 299 (25.9) 121 (20.5) 1.0 Reference 11 ( 7.8) 1.0 Reference 110 (24.5) 1.0 Reference  
 1+ 857 (74.1) 469 (79.5) 1.6 (1.1-2.1) 130 (92.2) 4.2 (1.9-9.3) 339 (75.5) 1.2 (0.9-1.7) <.001 
OC duration (yrs)‡           
 1-<3 242 (20.9) 126 (21.4) 1.5 (1.0-2.2) 31 (22.0) 3.0 (1.2-7.3) 95 (21.2) 1.3 (0.9-2.0)  
 3-<6 261 (22.6) 141 (23.9) 1.6 (1.1-2.4) 39 (27.7) 4.9 (2.1-11.6) 102 (22.7) 1.2 (0.8-1.9)  
 6+ 354 (30.6) 202 (34.2) 1.5 (1.1-2.2) 60 (42.6) 4.7 (2.0-10.8) 142 (31.6) 1.2 (0.8-1.7)  
 P for trend     .86   .17   .58  .10 
Age at first use (yrs)‡           
 22+ 166 (14.4) 79 (13.4) 1.3 (0.8-2.1) 20 (14.2) 3.5 (1.4-9.1) 59 (13.1) 1.1 (0.7-1.8)  
 18-<22 499 (43.2) 270 (45.8) 1.4 (1.0-2.0) 75 (53.2) 3.7 (1.7-8.5) 195 (43.4) 1.1 (0.8-1.6)  
 <18 192 (16.6) 120 (20.3) 2.3 (1.5-3.5) 35 (24.8) 6.4 (2.6-15.6) 85 (18.9) 1.8 (1.2-2.8)  
 P for trend     .02   .12   .04  .93 
Years since first use‡           
 <20 721 (62.4) 368 (62.4) 1.5 (1.1-2.1) 108 (76.6) 4.2 (1.9-9.5) 260 (57.9) 1.2 (0.8-1.7)  
 20+ 136 (11.8) 101 (17.1) 1.8 (1.2-2.9) 22 (15.6) 4.2 (1.6-10.8) 79 (17.6) 1.6 (1.0-2.5) .45 
Years since last use‡           
 Current 117 (10.1) 43 (  7.3) 1.2 (0.6-2.1) 16 (11.3) 4.5 (1.6-13.1) 27 (  6.0) 0.8 (0.4-1.5)  
 1-<10 388 (33.6) 210 (35.6) 1.7 (1.2-2.4) 62 (44.0) 5.1 (2.2-11.6) 148 (33.0) 1.3 (0.9-1.9)  
 10-<15 240 (20.8) 148 (25.1) 1.7 (1.1-2.4) 41 (29.1) 4.2 (1.7-9.9) 107 (23.8) 1.4 (0.9-2.1)  
 15+ 112 (  9.7) 68 (11.5) 1.3 (0.8-2.1) 11 ( 7.8) 2.1 (0.7-6.2) 57 (12.7) 1.2 (0.7-2.0)  
 P for trend     .95   .15   .46  .07 
 
Among women 41-45 years of age 
 
Oral contraceptive use n=413 n=307 n=46 n=261 
 
OC use (yrs)           
 Never/<1 108 (26.2) 76 (24.8) 1.0 Reference 11 (23.9) 1.0 Reference 65 (25.0) 1.0 Reference  
 1+ 305 (73.8) 230 (75.2) 1.0 (0.7-1.5) 35 (76.1) 0.9 (0.4-2.2) 195 (75.0) 1.0 (0.7-1.6) .93 
OC duration (yrs)‡           
 1-<3 85 (20.6) 58 (19.0) 0.9 (0.5-1.6) 4 ( 8.7) 0.4 (0.1-1.6) 54 (20.8) 1.0 (0.6-1.8)  
 3-<6 96 (23.2) 79 (25.8) 1.2 (0.7-2.0) 12 (26.1) 1.1 (0.4-3.0) 67 (25.8) 1.2 (0.7-2.1)  
 6+ 124 (30.0) 93 (30.4) 0.9 (0.6-1.6) 19 (41.3) 1.3 (0.5-3.3) 74 (28.5) 0.9 (0.5-1.5)  
 P for trend     .91   .11   .65  .06 
Age at first use (yrs)‡           
 22+ 94 (22.8) 80 (26.1) 1.0 (0.6-1.8) 11 (23.9) 0.8 (0.3-2.5) 69 (26.5) 1.1 (0.6-1.9)  
 18-<22 175 (42.4) 120 (39.2) 1.0 (0.6-1.6) 17 (37.0) 0.9 (0.4-2.3) 103 (39.6) 1.0 (0.6-1.6)  
 <18 36 (  8.7) 30 (  9.8) 1.1 (0.6-2.3) 7 (15.2) 1.3 (0.4-4.9) 23 ( 8.8) 1.1 (0.5-2.3)  
 P for trend     .85   .57   1.0  .59 
Years since first use‡           
 <20 54 (13.1) 41 (13.4) 1.0 (0.5-1.9) 6 (13.0) 1.0 (0.3-3.6) 35 (13.5) 1.0 (0.5-1.9)  
 20+ 251 (60.8) 189 (61.8) 1.0 (0.7-1.6) 29 (63.0) 0.9 (0.4-2.2) 160 (61.5) 1.0 (0.7-1.6) .77 
Years since last use‡           
 Current 3 (  0.7) 0 (  0.0) 0.0 N/A 0 ( 0.0) 0.0 N/A 0 ( 0.0) 0.0 N/A  
 1-<10 57 (13.8) 42 (13.7) 1.0 (0.5-1.9) 10 (21.7) 1.8 (0.6-5.4) 32 (12.3) 0.8 (0.4-1.6)  
 10-<15 99 (24.0) 65 (21.2) 0.8 (0.5-1.5) 14 (30.4) 1.0 (0.4-2.8) 51 (19.6) 0.8 (0.5-1.5)  
 15+ 146 (35.4) 123 (40.2) 1.1 (0.7-1.8) 11 (23.9) 0.7 (0.2-1.8) 112 (43.1) 1.2 (0.8-2.0)  
 P for trend     .33   .08   .10  .01 
*Risk factors adjusted for age, family history of breast cancer, and breastfeeding history 
† Pheterogeneity (association of risk factor with triple-negative vs. non triple-negative breast cancer) 
‡ Ptrend and Pheterogeneity among OC users >1 year only 
 
 
 
 
 
 
